Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 281

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 281
---
-102 between 4 and 20 weeks after initial injection) |     | 134 (66.3%) |     | 152 (76.4%) |
| Number of censored patients(1)                                                           |     | 68 (33.7%)  |     | 47 (23.6%)  |
| Chi-Square                                                                               |     | P=0.026     |     |             |

Time (days) to Repeat Injection

| N                         |     |       134 (66.3%) |     |   152 (76.4%) |
| Mean (SD)                 |     |      67.0 (33.31) |     |  57.8 (31.69) |
| Median                    |     |              57.5 |     |          43.0 |
| Min, Max                  |     |           27, 143 |     |       26, 148 |
| 25th quantile (95% CI)(2) |     |       45 (43, 57) |     |   36 (34, 40) |
| 50th quantile (95% CI)(2) |     |      84 (71, 100) |     |   58 (50, 69) |
| 75th quantile (95% CI)(2) |     |    143 (141, 143) |     | 126 (87, 146) |
| Comparison to Placebo(3)  |     | 0.68 (0.54, 0.86) |     |               |
| (Hazard ratio [95% CI]):  |     |           P=0.001 |     |               |

| (1) | Censored patients are the following: (1) patients who do not receive a repeat injection of SP-102 and (2) patients who discontinued the study prior to Week 20 without receiving a repeat injection. |

192

| (2) | Quartiles are estimated using Kaplan-Meier estimation. |

| (3) | A Cox proportional hazards model was utilized to test the treatment difference while adjusting for site and 
 Pain Catastrophizing Scale (<30 or >30).                                                                    |

CI: confidence interval; ITT: intent-to-treat(randomized population); SD: standard deviation Responder Analysis (Change from Baseline in Mean NPRS, Average Daily Pain in Affected Leg) (